Page last updated: 2024-08-18

pyrazolanthrone and Diabetic Angiopathies

pyrazolanthrone has been researched along with Diabetic Angiopathies in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fukuda, D; Kusunose, K; Pham, PT; Sata, M; Shimabukuro, M; Soeki, T; Yagi, S; Yamada, H	1

Other Studies

1 other study(ies) available for pyrazolanthrone and Diabetic Angiopathies

Article	Year
Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice. Scientific reports, 2019, 08-01, Volume: 9, Issue:1 Topics: Animals; Anthracenes; Aorta; Cell Line; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelium, Vascular; Factor Xa; Factor Xa Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Knockout; Nitric Oxide Synthase Type III; Phosphorylation; Receptor, PAR-2; Rivaroxaban; Streptozocin; Vasodilation	2019

Article

Year

Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice.

Scientific reports, 2019, 08-01, Volume: 9, Issue:1

Topics: Animals; Anthracenes; Aorta; Cell Line; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelium, Vascular; Factor Xa; Factor Xa Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Knockout; Nitric Oxide Synthase Type III; Phosphorylation; Receptor, PAR-2; Rivaroxaban; Streptozocin; Vasodilation

2019